Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Businesswire) - Feb 27, 2025 - "For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023...For the twelve months ended December 31, 2024, net product sales were $216.2 million, up 36% from $158.5 million in 2023...Aurinia expects to report initial results from its Phase 1 study of AUR200 in the second quarter of 2025."
New P1 trial • Sales • Immunology • Lupus Nephritis
|